Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $11.00.

BDTX has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Black Diamond Therapeutics in a research report on Thursday, October 29th. Raymond James Financial restated an “outperform” rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Black Diamond Therapeutics in a research note on Friday, October 9th. TD Cowen reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Black Diamond Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th.

Black Diamond Therapeutics Price Performance

NASDAQ:BDTX opened at $1.90 on Thursday. Black Diamond Therapeutics has a 52-week low of $1.60 and a 52-week high of $4.94. The stock has a fifty day moving average of $1.93 and a 200 day moving average of $2.18.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. Equities analysts predict that Black Diamond Therapeutics will post -0.57 earnings per share for the current fiscal year.

Institutional Trading of Black Diamond Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Spark Investment Management LLC purchased a new position in shares of Black Diamond Therapeutics in the 2nd quarter worth about $29,000. Brookstone Capital Management bought a new position in shares of Black Diamond Therapeutics during the 1st quarter valued at about $30,000. Hsbc Holdings PLC purchased a new position in shares of Black Diamond Therapeutics during the 2nd quarter valued at about $46,000. Beacon Capital Management LLC raised its holdings in shares of Black Diamond Therapeutics by 64.0% during the 3rd quarter. Beacon Capital Management LLC now owns 25,615 shares of the company’s stock valued at $48,000 after buying an additional 10,000 shares in the last quarter. Finally, EFG International AG purchased a new position in shares of Black Diamond Therapeutics during the 2nd quarter valued at about $50,000. Hedge funds and other institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.

Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.